Gaia Griguolo
@GaiaGriguolo
Followers
737
Following
2K
Media
158
Statuses
810
MD, Medical Oncologist and Clinical/Translational Researcher
Padua, Veneto
Joined September 2018
RT @PTarantinoMD: Results from VIKTORIA-1 just announced by @celcuity. The addition of gedatolisib to 2L fulvestrant/palbo improved PFS fro….
0
41
0
RT @mirrorsmed: Gene expression profiling in a retrospective real-world cohort of #BreastCancer 🧠brain metastases and paired primary tumors….
0
5
0
RT @LoiSher: 🏁latest review from #loilab & our Spanish colleagues #vhio #bcsm @OncoAlert @TILsWorkGroup Biomarkers of response and resistan….
thebreastonline.com
Immune checkpoint inhibitors (ICIs) have recently been approved in subsets of patients with breast cancer (BC). Currently, programmed death ligand 1 (PD-L1) immunohistochemistry is used as a biomar...
0
8
0
RT @PTarantinoMD: Results from the VIKTORIA-1 phase 3 trial (2L fulv/palbo/geda vs fulv/geda vs fulv) to be disclosed next Monday https://t….
0
15
0
Finally out @ESMO_Open!.Gene-expression of breast cancer brain metastases: .-high rate of non-luminal subtypes -shift towards HER2-enriched (primary vs 🧠 mts).- high PAM50 basal-like sig associated with worse OS (overall and HR+/HER2- 🧠 mts).@OncoAlert.
1
9
42
RT @Icro_Meattini: Is stereotactic #radiosurgery the standard of care for #breastcancer patients with multiple brain met?. Honoured to cont….
0
11
0
RT @OncoAlert: Metabolic adaptations of brain metastasis. . Brain🧠 metastases present a significant clinical challe….
0
18
0
Great to see our meta-analysis on #HER2DX and the GIM12-TYPHER.trial from @CarmineDeA1 in this week's @OncoAlert RoundUp!.
The OncoAlert WEEKLY RoundUp 🚨 .Covering the TOP of the week July 18-24, 2025 . 👉REGISTER at OR . Discussing: 🫁🧬.✅News From Industry: FLAURA2 Update #NSCLC 🫁.✅Exercise in met #ProstateCancer.✅Surgery🆚RT☢️in Prostate
0
2
9
RT @OncoAlert: Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase I….
0
15
0
RT @OncoAlert: HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis . https:/….
0
22
0
RT @ElisaAgostinett: Out in @BCRJournal the results of a phase 1/2 trial testing palazestrant, a new endocrine therapy that retains a uniqu….
0
14
0
OncoAlert Weekly roundup now online!.
The OncoAlert WEEKLY RoundUp 🚨.Covering the TOP of the week July 11-17, 2025 . 👉REGISTER at OR Discussing:.✅TALAPRO2 in #ProstateCancer.✅Geriatric Assessment 👴.✅Molecular Landscape of Non Clear Cell Renal Carcinoma
0
4
7
RT @ESOncology: Applications open for the 𝗖𝗲𝗿𝘁𝗶𝗳𝗶𝗰𝗮𝘁𝗲 𝗼𝗳 𝗖𝗼𝗺𝗽𝗲𝘁𝗲𝗻𝗰𝗲 𝗶𝗻 𝗕𝗿𝗲𝗮𝘀𝘁 𝗖𝗮𝗻𝗰𝗲𝗿 (𝗖𝗖𝗕), developed with Ulm University. A unique academ….
0
1
0
PALMARES-2 study @Annals_Oncology. Real-world effectiveness of first-line palbociclib, ribociclib or abemaciclib plus ET in HR+/HER2- mBC. Different effectiveness of the three CDK4/6i observed in different clinical settings. @OncoAlert.
annalsofoncology.org
The cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) palbociclib, ribociclib and abemaciclib in combination with endocrine therapy (ET) are the standard-of-care, first-line treatment for patients...
1
9
21
RT @Icro_Meattini: Proud to share our @ESTRO_RT manifesto published in @RO_GreenJournal . A call to reposition radiation oncology at the h….
0
12
0
RT @Dr_ElvinaA: Hormone therapy & young-onset breast cancer (<55y). Lancet Oncology pooled data (n=459K):.🟢 Estrogen-only HT ↓ risk (HR 0.8….
0
3
0
Out on @TheLancetOncol.Meta-analysis of 11 studies (n=2,518 pts) confirms independent prognostic value of HER2DX in HER2+ early Bresst Cancer beyond pCR, T, N, and HR status. 6-yr EFS.🟢 Low risk: 93.6%.🔴 High risk: 82.9%.HR: 2.72 (p<0.0001).@OncoAlert.
0
0
2
RT @DrHBurstein: Many cancer patients are prescribed gabapentin for neuropathy symptoms. This finding of increased risk of dementia with g….
0
24
0
RT @OncoAlert: The OncoAlert🚨Weekly Round Up .Covering the TOP of the week July 4-10, 2025 . REGISTER at OR h….
0
19
0